Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential. While chemotherapy and targeted drugs have ...
Komzifti, a menin inhibitor, is FDA-approved for relapsed/refractory AML with NPM1 mutation, showing efficacy in the KO-MEN-001 trial. The trial reported a 21.4% CR plus CRh rate and a five-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results